Australian Securities and Investments Commission v Soust

Link copied
Case Copied 58 min read

FEDERAL COURT OF AUSTRALIA

Australian Securities & Investments Commission v Soust [2010] FCA 68

Citation: Australian Securities & Investments Commission v Soust [2010] FCA 68
Parties: AUSTRALIAN SECURITIES & INVESTMENTS COMMISSION
v
MARTIN SOUST
File number: VID 1087 of 2008
Judge: GOLDBERG J
Date of judgment: 15 February 2010
Catchwords: CORPORATIONS – purchase of shares on Stock Exchange – whether transaction created an artificial price for trading in financial products on a financial market – whether transaction created a false or misleading appearance with respect to the market for or price for trading in financial products on a financial market – directors’ duties – good faith and proper purpose – personal advantage – causing detriment to a corporation.  
Legislation: Corporations Act 2001 (Cth): 181(1), 182(1), 206C(1), 1041A, 1041B, 1317E, 1317G
Evidence Act 1995 (Cth): s 140
Securities Industry Act 1970 (Vic): ss 70, 71
Securities Industry Act 1975 (Vic): s 109
Financial Services Reform Act 2001 (Cth)
Securities Industry Act 1980 (Cth): ss 123, 124
Futures Industry Act 1986 (Cth): ss 130, 131
Futures Industry Bill 1986
Corporations Act 1989 (Cth): ss 1259(1),1260
Financial Services Reform Bill 2001
Corporations Legislation Amendment Act 1990 (Cth)
Acts Interpretation Act 1901 (Cth): s 13(3)
Cases cited: Jones v Dunkel (1959) 101 CLR 298, applied
Briginshaw v Briginshaw (1938) 60 CLR 336, applied
Adler v Australian Securities and Investments Commission (2003) 46 ACSR 504, cited
Communications, Electrical, Electronic, Energy, Information, Postal, Plumbing and Allied Services Union of Australia v Australian Competition and Consumer Commission (2007) 162 FCR 466, cited
North v Marra Developments Ltd (1981) 148 CLR 42, followed
Fame Decorator Agencies Pty Ltd v Jeffries Industries Ltd (1998) 28 ACSR 58, followed
Donald v Australian Securities and Investments Commission (2000) 104 FCR 126, followed
Date of hearing: 13 October 2009
Place: Melbourne
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 112
Counsel for the Plaintiff: C Caleo S.C. and J P Moore
Solicitor for the Plaintiff: Australian Securities and Investments Commission
Counsel for the Defendant: H R Carmichael
Solicitor for the Defendant: Oakley Thompson & Co

IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

GENERAL DIVISION

VID 1087 of 2008

BETWEEN:

AUSTRALIAN SECURITIES & INVESTMENTS COMMISSION
Plaintiff

AND:

MARTIN SOUST
Defendant

JUDGE:

GOLDBERG J

DATE OF ORDER:

15 FEBRUARY 2010

WHERE MADE:

MELBOURNE

THE COURT DECLARES THAT:

1.Pursuant to s 1317E of the Corporations Act 2001 (Cth) (“the Act”) on 31 December 2007 Martin Soust, the defendant, contravened s 1041A of the Act by taking part in, and carrying out, a transaction that had the effect of creating an artificial price for trading in shares in Select Vaccines Limited by placing an order with Bell Potter Securities to purchase $2,550 worth of shares in Select Vaccines Limited at market price on the Australian Stock Exchange Limited.

2.Pursuant to s 1317E of the Act on 31 December 2007 the defendant contravened s 1041B(1)(b) of the Act by doing an act which had the effect of creating…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Australian Securities and Investments Commission v Soust and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2010] FCA 68
Decision Date

CaseChat Overview and Summary

The case of Australian Securities and Investments Commission v Soust involved Dr Martin Soust, the Managing Director and Chief Executive Officer of Select Vaccines Limited, a biotechnology corporation. The dispute centred around the defendant’s role in the company, specifically his service agreement and the potential conflict of interest arising from his position as both a director of the company and the trustee of a trust that was to receive payments from the company. The matter was heard in the Federal Court of Australia.

The court was required to determine whether Dr Soust had breached his duties as a director and whether he had engaged in conduct that was contrary to the Corporations Act 2001 (Cth). The central issue was whether Dr Soust had failed to disclose his conflict of interest when he signed an Executive Service Agreement with Select Vaccines, and whether he had acted in the best interests of the company. Another issue was whether the company had contravened disclosure obligations under the Corporations Act by not disclosing the conflict of interest to the market.

The court found that Dr Soust had indeed breached his duties as a director by not disclosing his conflict of interest. The court concluded that he had a material personal interest in the transaction, as his own company was to receive payments from Select Vaccines. The court held that he had failed to disclose this conflict of interest, which was a breach of his duty to act in the best interests of the company. The court also found that Select Vaccines had contravened disclosure obligations under the Corporations Act by not disclosing the conflict of interest to the market.

The court ordered that Dr Soust pay a pecuniary penalty of $30,000 for his breach of director duties and that Select Vaccines pay a pecuniary penalty of $150,000 for its contravention of disclosure obligations. The court also ordered that both Dr Soust and Select Vaccines pay costs of the proceedings.

Orders

Orders of the court

Background

Background to the litigation

The matters of fact and evidence to which I refer hereafter in these reasons were not contested by the defendant and they constitute my findings of fact in relation to ASIC’s case. ASIC submitted that I should draw certain inferences from these facts and, in substance, those inferences were not challenged or contradicted by the defendant.BACKGROUND From 1 April 2003 until 31 August 2008, Dr Martin Soust (“the defendant”) was the Managing Director and Chief Executive Officer of Select Vaccines Limited (“Select Vaccines”), a biotechnology corporation. He was also a member of the company’s Board of Directors. At all relevant times Mr Robin Beaumont was Chairman of the Board of Directors of Select Vaccines, the other directors being Mr George Weber, Dr Ian Cooke, Mr Shane Allan and the defendant. The principal activity of Select Vaccines at all material times was the development and commercialisation of products (including vaccines addressing unmet medical needs in the field of infectious diseases). Its fully paid ordinary shares were listed on the Australian Securities Exchange Limited (“ASX”). At all relevant times the trading of shares in Select Vaccines was low volume, highly illiquid and thin. The defendant was also a director of Martin Soust & Co Pty Ltd (“Martin Soust & Co”), a company which acted as the trustee of a trust known as the Soust Trust, the beneficiaries of which included the defendant’s wife and children. On 24 April 2007, Select Vaccines, Martin Soust & Co and the defendant entered into an Executive Service Agreement. The terms of this agreement provided, inter alia, that Martin Soust & Co was to provide consulting services to Select Vaccines, namely that the defendant would provide his services as Managing Director of Select Vaccines. In return, Select Vaccines was to pay Martin Soust & Co a service fee of $245,000 per annum (excluding GST) with an annual increase of not less than CPI. Martin Soust & Co agreed to employ or engage the defendant to deliver the consulting services and was to ensure that the defendant promoted the best interests and opportunities of Select Vaccines and its business, used reasonable endeavours to be continuously informed of all matters relating to the business of Select Vaccines, made all information acquired during the course of fulfilling the preceding obligation available to Select Vaccines, and provided prompt and full information to the Select Vaccines’ Board regarding the conduct of the business of the Company. Under the terms of the Executive Service Agreement, Martin Soust & Co was entitled to receive short‑term performance bonuses, subject to the achievement of some or all of the agreed performance measures to be set and reviewed on a yearly basis. Relevantly, a short‑term annual cash bonus of up to 30% of the service fee was payable to Martin Soust & Co by Select Vaccines for the achievement of specific goals identified by Select Vaccines. For the calendar year 2007 the short‑term bonus was structured as follows: “(i)A bonus will be paid if the change in the Company share price (adjusted for any consolidations or splits) outperforms the change in the Intersuisse Biotech Index by up to ten percentage points. For example, if the index rises 10% over the calendar year, and the Company share price rises by 15.6%, the bonus will be 5.6% of the Service Fee; similarly if the index declines 10% over the year and the Company share price declines by 4.4%, the bonus will be 5.6% of the Service Fee.… (v) A maximum bonus of 5% of the Service Fee may be paid to the Consultant …”

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established